In Annex VI to Regulation (EC) No 1272/2008, Table 3 of Part 3 is amended as follows:
the following entries are inserted:
| Index No | Chemical name | EC No | CAS No | Classification | Labelling | Specific Conc. Limits, M-factors and ATE | Notes | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Hazard Class and Category Code(s) | Hazard statement Code(s) | Pictogram, Signal Word Code(s) | Hazard statement Code(s) | Suppl. Hazard statement Code(s) | ||||||
| ‘007-030-00-3 | nitric acid …% [C ≤ 70 %] | 231-714-2 | 7697-37-2. | Ox. Liq. 3 Acute Tox. 3 Skin Corr. 1A | H272 H331 H314 | GHS03 GHS06 GHS05 Dgr | H272 H331 H314 | EUH071 | Ox. Liq. 3; H272: C ≥ 65 % inhalation: ATE = 2,65 mg/L (vapours) Skin Corr. 1A; H314: C ≥ 20 % Skin Corr. 1B; H314: 5 % ≤ C < 20 % | B’ |
| ‘014-048-00-5 | silicon carbide fibres (with diameter < 3 μm, length > 5 μm and aspect ratio ≥ 3:1) | 206-991-8 | 409-21-2 308076-74-6 | Carc. 1B | H350i | GHS08 Dgr | H350i’ | |||
| ‘014-049-00-0 | trimethoxyvinylsilane; trimethoxy(vinyl)silane | 220-449-8 | 2768-02-7 | Skin Sens. 1B | H317 | GHS07 Wng | H317’ | |||
| ‘014-050-00-6 | tris(2-methoxyethoxy)vinylsilane; 6-(2-methoxyethoxy)-6-vinyl-2,5,7,10-tetraoxa-6-silaundecane | 213-934-0 | 1067-53-4 | Repr. 1B | H360FD | GHS08 Dgr | H360FD’ | |||
| ‘016-098-00-3 | dimethyl disulphide | 210-871-0 | 624-92-0 | Flam. Liq. 2 Acute Tox. 3 Acute Tox. 3 STOT SE 3 STOT SE 1 Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H225 H331 H301 H336 H370 (upper respiratory tract, inhalation) H319 H317 H400 H410 | GHS02 GHS06 GHS08 GHS09 Dgr | H225 H331 H301 H336 H370 (upper respiratory tract, inhalation) H319 H317 H410 | inhalation: ATE = 5 mg/L (vapours) oral: ATE = 190 mg/kg bw M = 1 M = 10’ | ||
| ‘029-024-00-X | granulated copper; [particle length: from 0,9 mm to 6,0 mm; particle width: from 0,494 to 0,949 mm] | 231-159-6 | 7440-50-8 | Aquatic Chronic 2 | H411 | GHS09 | H411’ | |||
| ‘029-025-00-5 | bis(N-hydroxy-N-nitrosocyclohexylaminato-O,O’)copper; bis(N-cyclohexyl-diazenium-dioxy)-copper; [Cu-HDO] | 239-703-4 | 312600-89-8 15627-09-5 | Flam. Sol. 1 Acute Tox. 4 STOT RE 2 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H228 H302 H373 (liver) H318 H400 H410 | GHS02 GHS07 GHS08 GHS05 GHS09 Dgr | H228 H302 H373(liver) H318 H410 | oral: ATE = 360 mg/kg bw M = 1 M = 1’ | ||
| ‘050-031-00-9 | dioctyltin dilaurate; [1] stannane, dioctyl-, bis(coco acyloxy) derivs. [2] | 222-883-3 [1] 293-901-5 [2] | 3648-18-8 [1] 91648-39-4 [2] | Repr. 1B STOT RE 1 | H360D H372 (immune system) | GHS08 Dgr | H360D H372 (immune system)’ | |||
| ‘601-092-00-0 | dibenzo[def,p]chrysene; dibenzo[a,l]pyrene | 205-886-4 | 191-30-0 | Carc. 1B Muta. 2 | H350 H341 | GHS08 Dgr | H350 H341 | Carc. 1B; H350: C ≥ 0,001 %’ | ||
| ‘603-237-00-3 | ipconazole (ISO); (1RS,2SR,5RS;1RS,2SR,5SR)-2-(4-chlorobenzyl)-5-isopropyl-1-(1H-1,2,4-triazol-1-ylmethyl)cyclopentanol | - | 125225-28-7 115850-69-6 115937-89-8 | Repr. 1B Acute Tox. 4 STOT RE 2 Aquatic Chronic 1 | H360D H302 H373 (eyes, skin, liver) H410 | GHS08 GHS07 GHS09 Dgr | H360D H302 H373 (eyes, skin, liver) H410 | oral: ATE = 500 mg/kg bw M = 100’ | ||
| ‘603-238-00-9 | bis(2-(2-methoxyethoxy)ethyl)ether; tetraglyme | 205-594-7 | 143-24-8 | Repr. 1B | H360FD | GHS08 Dgr | H360FD’ | |||
| ‘603-239-00-4 | paclobutrazol (ISO); (2RS,3RS)-1-(4-chlorophenyl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl)pentan-3-ol | - | 76738-62-0 | Repr. 2 Acute Tox. 4 Acute Tox. 4 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H361d H332 H302 H319 H400 H410 | GHS08 GHS07 GHS09 Wng | H361d H332 H302 H319 H410 | inhalation: ATE = 3,13 mg/L (dusts or mists) oral: ATE = 490 mg/kg bw M = 10 M = 10’ | ||
| ‘603-240-00-X | 2,2-bis(bromomethyl)propane-1,3-diol | 221-967-7 | 3296-90-0 | Carc. 1B Muta. 1B | H350 H340 | GHS08 Dgr | H350 H340’ | |||
| ‘603-241-00-5 | geraniol; (2E)-3,7-dimethylocta-2,6-dien-1-ol | 203-377-1 | 106-24-1 | Skin Sens. 1 | H317 | GHS07 Wng | H317’ | |||
| ‘605-041-00-3 | 2-(4-tert-butylbenzyl)propionaldehyde | 201-289-8 | 80-54-6 | Repr. 1B | H360Fd | GHS08 Dgr | H360Fd’ | |||
| ‘607-738-00-8 | MCPA-thioethyl (ISO); S-ethyl (4-chloro-2-methylphenoxy)ethanethioate; S-ethyl 4-chloro-o-tolyloxythioacetate | 246-831-4 | 25319-90-8 | Acute Tox. 4 STOT RE. 2 Aquatic Acute 1 Aquatic Chronic 1 | H302 H373 (liver) H400 H410 | GHS07 GHS08 GHS09 Wng | H302 H373 (liver) H410 | oral: ATE = 450 mg/kg bw M = 10 M = 10’ | ||
| ‘607-740-00-9 | diisooctyl phthalate | 248-523-5 | 27554-26-3 | Repr. 1B | H360FD | GHS08 Dgr | H360FD’ | |||
| ‘607-741-00-4 | 4-{[(6-chloropyridin-3-yl)methyl](2,2-difluoroethyl)amino}furan-2(5H)-one; flupyradifurone | - | 951659-40-8 | Acute Tox. 4 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 | H302 H373 (muscle) H400 H410 | GHS07 GHS08 GHS09 Wng | H302 H373 (muscle) H410 | oral: ATE = 500 mg/kg bw M = 10 M = 10’ | ||
| ‘607-742-00-X | thiencarbazone-methyl (ISO); methyl 4-[(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1H-1,2,4-triazol-1-yl)carbonylsulfamoyl]-5- methylthiophene-3-carboxylate | - | 317815-83-1 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Wng | H410 | M = 1000 M = 1000’ | ||
| ‘607-743-00-5 | L-(+)-lactic acid; (2S)-2-hydroxypropanoic acid | 201-196-2 | 79-33-4 | Skin Corr. 1C Eye Dam. 1 | H314 H318 | GHS05 Dgr | H314 | EUH071’ | ||
| ‘607-744-00-0 | 2-methoxyethyl acrylate | 221-499-3 | 3121-61-7 | Flam. Liq. 3 Muta. 2 Repr. 1B Acute Tox. 3 Acute Tox. 4 Skin Corr. 1C Eye Dam. 1 Skin Sens. 1 | H226 H341 H360FD H331 H302 H314 H318 H317 | GHS02 GHS05 GHS06 GHS08 Dgr | H226 H341 H360FD H331 H302 H314 H317 | EUH071 | inhalation: ATE = 2,7 mg/L (vapours) oral: ATE = 404 mg/kg bw’ | |
| ‘607-745-00-6 | glyoxylic acid …% | 206-058-5 | 298-12-4 | Eye Dam. 1 Skin Sens. 1B | H318 H317 | GHS05 GHS07 Dgr | H318 H317 | B’ | ||
| ‘607-746-00-1 | sodium N-(hydroxymethyl)glycinate; [formaldehyde released from sodium N-(hydroxymethyl)glycinate] | 274-357-8 | 70161-44-3 | Carc. 1B Muta. 2 Acute Tox. 4 Acute Tox. 4 STOT SE 3 Skin Irrit. 2 Eye Irrit. 2 Skin Sens. 1 | H350 H341 H332 H302 H335 H315 H319 H317 | GHS08 GHS07 Dgr | H350 H341 H332 H302 H335 H315 H319 H317 | inhalation: ATE = 3 mg/L (dusts or mists) oral: ATE = 1100 mg/kg bw | 8 9’ | |
| ‘611-181-00-6 | potassium (oxido-NNO-azoxy)cyclohexane; cyclohexylhydroxydiazene 1-oxide, potassium salt; [K-HDO] | - | 66603-10-9 | Flam. Sol. 1 Acute Tox. 3 STOT RE 2 Skin Irrit. 2 Eye Dam. 1 Aquatic Chronic 2 | H228 H301 H373 (liver) H315 H318 H411 | GHS02 GHS06 GHS08 GHS05 GHS09 Dgr | H228 H301 H373 (liver) H315 H318 H411 | oral: ATE = 136 mg/kg bw’ | ||
| ‘612-294-00-3 | mecetronium etilsulfate; N-ethyl-N,N-dimethylhexadecan-1-aminium ethyl sulfate; mecetronium ethyl sulphate; [MES] | 221-106-5 | 3006-10-8 | Skin Corr. 1 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H314 H318 H400 H410 | GHS05 GHS09 Dgr | H314 H410 | EUH071 | M = 100 M = 1000’ | |
| ‘613-331-00-6 | (2RS)-2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-1-(1H-1,2,4-triazol-1-yl)propan-2-ol; mefentrifluconazole | - | 1417782-03-6 | Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H317 H400 H410 | GHS07 GHS09 Wng | H317 H410 | M = 1 M = 1’ | ||
| ‘613-332-00-1 | oxathiapiprolin (ISO); 1-(4-{4-[5-(2,6-difluorophenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone | - | 1003318-67-9 | Aquatic Chronic 1 | H410 | GHS09 Wng | H410 | M = 1’ | ||
| ‘613-333-00-7 | pyrithione zinc; (T-4)-bis[1-(hydroxy-.kappa.O)pyridine-2(1H)-thionato-.kappa.S]zinc | 236-671-3 | 13463-41-7 | Repr. 1B Acute Tox. 2 Acute Tox. 3 STOT RE 1 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 | H360D H330 H301 H372 H318 H400 H410 | GHS08 GHS06 GHS05 GHS09 Dgr | H360D H330 H301 H372 H318 H410 | inhalation: ATE = 0,14 mg/L (dusts or mists) oral: ATE = 221 mg/kg bw M = 1000 M = 10’ | ||
| ‘613-334-00-2 | flurochloridone (ISO); 3-chloro-4-(chloromethyl)-1-[3-(trifluoromethyl)phenyl]pyrrolidin-2-one | 262-661-3 | 61213-25-0 | Repr. 1B Acute Tox. 4 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H360FD H302 H317 H400 H410 | GHS08 GHS07 GHS09 Dgr | H360FD H302 H317 H410 | oral: ATE = 500 mg/kg bw M = 100 M = 100’ | ||
| ‘613-335-00-8 | 4,5-dichloro-2-octyl-2H-isothiazol-3-one; [DCOIT] | 264-843-8 | 64359-81-5 | Acute Tox. 2 Acute Tox. 4 Skin Corr. 1 Eye Dam. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1 | H330 H302 H314 H318 H317 H400 H410 | GHS06 GHS05 GHS09 Dgr | H330 H302 H314 H317 H410 | EUH071 | inhalation: ATE = 0,16 mg/L (dusts or mists) oral: ATE = 567 mg/kg bw Skin Irrit. 2; H315: 0,025 % ≤ C < 5 % Eye Irrit. 2; H319: 0,025 % ≤ C < 3 % Skin Sens. 1A; H317: C ≥ 0,0015 % M = 100 M = 100’ | |
| ‘613-336-00-3 | 2-methyl-1,2-benzothiazol-3(2H)-one; [MBIT] | - | 2527-66-4 | Acute Tox. 4 Acute Tox. 3 Skin Corr. 1C Eye Dam. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 2 | H312 H301 H314 H318 H317 H400 H411 | GHS06 GHS05 GHS09 Dgr | H312 H301 H314 H317 H410 | EUH071 | dermal: ATE = 1100 mg/kg bw oral: ATE = 175 mg/kg bw Skin Sens. 1A; H317: C ≥ 0,0015 % M = 1’ | |
| ‘616-228-00-4 | 3-(difluoromethyl)-1-methyl-N-(3',4',5'-trifluorobiphenyl-2-yl)pyrazole-4-carboxamide; fluxapyroxad | - | 907204-31-3 | Lact. Aquatic Acute 1 Aquatic Chronic 1 | H362 H400 H410 | GHS09 Wng | H362 H410 | M = 1 M = 1’ | ||
| ‘616-230-00-5 | N-(hydroxymethyl)acrylamide; methylolacrylamide; [NMA] | 213-103-2 | 924-42-5 | Carc. 1B Muta. 1B STOT RE 1 | H350 H340 H372 (peripheral nervous system) | GHS08 Dgr | H350 H340 H372 (peripheral nervous system)’ | |||
| ‘616-231-00-0 | 5-fluoro-1,3-dimethyl-N-[2-(4-methylpentan-2-yl)phenyl]-1H-pyrazole-4-carboxamide; 2'-[(RS)-1,3-dimethylbutyl]-5-fluoro-1,3-dimethylpyrazole-4-carboxanilide; penflufen | - | 494793-67-8 | Carc. 2 Aquatic Acute 1 Aquatic Chronic 1 | H351 H400 H410 | GHS08 GHS09 Wng | H351 H410 | M = 1 M = 1’ | ||
| ‘616-232-00-6 | iprovalicarb (ISO); isopropyl [(2S)-3-methyl-1-{[1-(4-methylphenyl)ethyl]amino}-1-oxobutan-2-yl]carbamate | - | 140923-17-7 | Carc. 2 | H351 | GHS08 Wng | H351’ | |||
| ‘616-233-00-1 | silthiofam (ISO); N-allyl-4,5-dimethyl-2-(trimethylsilyl)thiophene-3-carboxamide | - | 175217-20-6 | STOT RE 2 Aquatic Chronic 2 | H373 H411 | GHS08 GHS09 Wng | H373 H411’ | |||
| ‘650-057-00-6 | Margosa, ext. [cold-pressed oil of Azadirachta indica seeds without shells extracted with super-critical carbon dioxide] | 283-644-7 | 84696-25-3 | Aquatic Chronic 3 | H412 | H412’ | ||||
the entries corresponding to index numbers 007-004-00-1; 014-018-00-1; 015-134-00-5; 015-181-00-1; 050-021-00-4; 050-027-00-7; 082-013-00-1; 603-014-00-0; 603-065-00-9; 605-019-00-3; 607-177-00-9; 607-256-00-8; 607-314-00-2; 609-041-00-4; 609-064-00-X; 613-112-00-5; 613-115-00-1; 613-125-00-6; 613-202-00-4; 613-259-00-5; 616-014-00-0 and 617-006-00-X are replaced by the following entries respectively:
| Index No | Chemical name | EC No | CAS No | Classification | Labelling | Specific Conc. Limits, M-factors and ATE | Notes | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Hazard Class and Category Code(s) | Hazard statement Code(s) | Pictogram, Signal Word Code(s) | Hazard statement Code(s) | Suppl. Hazard statement Code(s) | ||||||
| ‘007-004-00-1 | nitric acid …% [C > 70 %] | 231-714-2 | 7697-37-2 | Ox. Liq. 2 Acute Tox. 1 Skin Corr. 1A | H272 H330 H314 | GHS03 GHS06 GHS05 Dgr | H272 H330 H314 | EUH071 | Ox. Liq. 2; H272: C ≥ 99 % Ox. Liq. 3; H272: 70 % ≤ C < 99 % | B’ |
| ‘014-018-00-1 | octamethylcyclotetrasiloxane; [D4] | 209-136-7 | 556-67-2 | Repr. 2 Aquatic Chronic 1 | H361f *** H410 | GHS08 GHS09 Wng | H361f *** H410 | M = 10’ | ||
| ‘015-134-00-5 | pirimiphos-methyl (ISO); O-[2-(diethylamino)-6-methylpyrimidin-4-yl] O,O-dimethyl phosphorothioate | 249-528-5 | 29232-93-7 | Acute Tox. 4 STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H372 (nervous system) H400 H410 | GHS07 GHS08 GHS09 Dgr | H302 H372 (nervous system) H410 | oral: ATE = 1414 mg/kg bw M = 1000 M = 1000’ | ||
| ‘015-181-00-1 | phosphine | 232-260-8 | 7803-51-2 | Flam. Gas 1 Press. Gas Acute Tox. 1 Skin Corr. 1B Aquatic Acute 1 | H220 H330 H314 H400 | GHS02 GHS04 GHS06 GHS05 GHS09 Dgr | H220 H330 H314 H400 | inhalation: ATE = 10 ppmV (gases) | U’ | |
| ‘050-021-00-4 | dichlorodioctylstannane | 222-583-2 | 3542-36-7 | Repr. 1B Acute Tox. 2 STOT RE 1 Aquatic Chronic 3 | H360D H330 H372 ** H412 | GHS08 GHS06 Dgr | H360D H330 H372 ** H412 | Repr. 1B; H360 D: C ≥ 0,03 % inhalation: ATE = 0,098 mg/L (dusts or mists)’ | ||
| ‘050-027-00-7 | 2-ethylhexyl 10-ethyl-4,4-dioctyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradecanoate; [DOTE] | 239-622-4 | 15571-58-1 | Repr. 1B STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 | H360D H372 (immune system) H400 H410 | GHS08 GHS09 Dgr | H360D H372 (immune system) H410’ | |||
| ‘082-013-00-1 | lead powder; [particle diameter < 1 mm] | 231-100-4 | 7439-92-1 | Repr. 1A Lact. Aquatic Acute 1 Aquatic Chronic 1 | H360FD H362 H400 H410 | GHS08 GHS09 Dgr | H360FD H362 H410 | Repr. 1A; H360D: C ≥ 0,03 % M = 1 M = 10’ | ||
| ‘603-014-00-0 | 2-butoxyethanol; ethylene glycol monobutyl ether | 203-905-0 | 111-76-2 | Acute Tox. 4* Acute Tox. 4 Skin Irrit. 2 Eye Irrit. 2 | H332 H302 H315 H319 | GHS07 Wng | H332 H302 H315 H319 | oral: ATE = 1200 mg/kg bw’ | ||
| ‘603-065-00-9 | m-bis(2,3-epoxypropoxy)benzene; resorcinol diglycidyl ether | 202-987-5 | 101-90-6 | Carc. 1B Muta. 2 Acute Tox. 3 Acute Tox. 4 Skin Irrit. 2 Eye Irrit. 2 Skin Sens. 1 Aquatic Chronic 3 | H350 H341 H311 H302 H315 H319 H317 H412 | GHS08 GHS06 Dgr | H350 H341 H311 H302 H315 H319 H317 H412 | dermal: ATE = 300 mg/kg bw oral: ATE = 500 mg/kg bw’ | ||
| ‘607-177-00-9 | tribenuron-methyl (ISO); methyl 2-[N-(4-methoxy-6-methyl-1,3,5-triazin-2-yl)-N-methylcarbamoylsulfamoyl]benzoate | 401-190-1 | 101200-48-0 | STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H373 H317 H400 H410 | GHS08 GHS07 GHS09 Wng | H373 H317 H410 | M = 100 M = 100’ | ||
| ‘607-256-00-8 | azoxystrobin (ISO); methyl (E)-2-{2-[6-(2-cyanophenoxy)pyrimidin-4-yloxy]phenyl}-3-methoxyacrylate | - | 131860-33-8 | Acute Tox. 3 Aquatic Acute 1 Aquatic Chronic 1 | H331 H400 H410 | GHS06 GHS09 Dgr | H331 H410 | inhalation: ATE = 0,7 mg/L (dusts or mists) M = 10 M = 10’ | ||
| ‘607-314-00-2 | ethofumesate (ISO); (RS)-2-ethoxy-2,3-dihydro-3,3-dimethylbenzofuran-5-yl methanesulfonate | 247-525-3 | 26225-79-6 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Wng | H410 | M = 1 M = 1’ | ||
| ‘609-041-00-4 | 2,4-dinitrophenol | 200-087-7 | 51-28-5 | Acute Tox. 3 * Acute Tox. 3 Acute Tox. 2 STOT RE 1 Aquatic Acute 1 | H331 H311 H300 H372 H400 | GHS06 GHS08 GHS09 Dgr | H331 H311 H300 H372 H400 | dermal: ATE = 300 mg/kg bw oral: ATE = 30 mg/kg bw’ | ||
| ‘609-064-00-X | mesotrione (ISO); 2-[4-(methylsulfonyl)-2-nitrobenzoyl]-1,3-cyclohexanedione | - | 104206-82-8 | Repr. 2 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 | H361d H373 (eyes, nervous system) H400 H410 | GHS08 GHS09 Wng | H361d H373 (eyes, nervous system) H410 | M = 10 M = 10’ | ||
| ‘613-112-00-5 | octhilinone (ISO); 2-octyl-2H-isothiazol-3-one; [OIT] | 247-761-7 | 26530-20-1 | Acute Tox. 2 Acute Tox. 3 Acute Tox. 3 Skin Corr. 1 Eye Dam. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1 | H330 H311 H301 H314 H318 H317 H400 H410 | GHS06 GHS05 GHS09 Dgr | H330 H311 H301 H314 H317 H410 | EUH071 | inhalation: ATE = 0,27 mg/L (dusts or mists) dermal: ATE = 311 mg/kg bw oral: ATE = 125 mg/kg bw Skin Sens. 1A; H317: C ≥ 0,0015 % M = 100 M = 100’ | |
| ‘613-115-00-1 | hymexazol (ISO); 3-hydroxy-5-methylisoxazole | 233-000-6 | 10004-44-1 | Repr. 2 Acute Tox. 4 Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 | H361d H302 H318 H317 H411 | GHS08 GHS07 GHS05 GHS09 Dgr | H361d H302 H318 H317 H411 | oral: ATE = 1600 mg/kg bw’ | ||
| ‘613-125-00-6 | hexythiazox (ISO); trans-5-(4-chlorophenyl)-N-cyclohexyl-4-methyl-2-oxo-3-thiazolidine-carboxamide | - | 78587-05-0 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Wng | H410 | M = 1 M = 1’ | ||
| ‘613-202-00-4 | pymetrozine (ISO); (E)-4,5-dihydro-6-methyl-4-(3-pyridylmethyleneamino)-1,2,4-triazin-3(2H)-one | - | 123312-89-0 | Carc. 2 Repr. 2 Aquatic Chronic 1 | H351 H361fd H410 | GHS08 GHS09 Wng | H351 H361fd H410 | M = 1’ | ||
| ‘613-259-00-5 | imiprothrin (ISO); reaction mass of: [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1R)-cis-chrysanthemate; [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1R)-trans-chrysanthemate | 428-790-6 | 72963-72-5 | Carc. 2 Acute Tox. 4 Acute Tox. 4 STOT SE 2 Aquatic Acute 1 Aquatic Chronic 1 | H351 H332 H302 H371 (nervous system; oral, inhalation) H400 H410 | GHS08 GHS07 GHS09 Wng | H351 H332 H302 H371 (nervous system; oral, inhalation) H410 | inhalation: ATE = 1,4 mg/L (dusts or mists) oral: ATE = 550 mg/kg bw M = 10 M = 10’ | ||
| ‘616-014-00-0 | butanone oxime; ethyl methyl ketoxime; ethyl methyl ketone oxime | 202-496-6 | 96-29-7 | Carc. 1B Acute Tox. 4 Acute Tox. 3 STOT SE 3 STOT SE 1 STOT RE 2 Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 | H350 H312 H301 H336 H370 (upper respiratory tract) H373 (blood system) H315 H318 H317 | GHS08 GHS06 GHS05 Dgr | H350 H312 H301 H336 H370 (upper respiratory tract) H373 (blood system) H315 H318 H317 | dermal: ATE = 1100 mg/kg bw oral: ATE = 100 mg/kg bw’ | ||
| ‘617-006-00-X | bis(α,α-dimethylbenzyl) peroxide | 201-279-3 | 80-43-3 | Org. Perox. F Repr. 1B Skin Irrit. 2 Eye Irrit. 2 Aquatic Chronic 2 | H242 H360D H315 H319 H411 | GHS02 GHS08 GHS07 GHS09 Dgr | H242 H360D H315 H319 H411’ | |||
the entries corresponding to index numbers 601-064-00-8 and 607-693-00-4 are deleted.